ONEIDA >> There is an abundance of groundbreaking research going on at the Cardiac Research Institute, or Masonic Medical Research Laboratory in Utica. Myron Thurston III, the assistant director of development and communications at the institute, will host the next Community Media Lab to share some of the experimental cardiology projects and research with the public, as well as educate them on heart health.

The Community Media Lab will take place Feb. 27 at 6 p.m. at the Oneida Daily Dispatch office, 130 Broad St. in Oneida. It is free and open to the public.

Thurston will explain what were doing in the area of cardiac arrhythmias and irregular heartbeats. An arrhythmia is an abnormal heart rhythm caused by electrical instability within the heart.

Some of the most significant work done at the lab is with stem cell research and bio-engineering. Scientists at the lab are working on using skin cells to create genetically-matching heart cells that can ideally be used for regenerative therapy for failing hearts.

Thurston says the idea is that if the scientists can create a heart or organ made from the persons cells the body wouldnt reject it.

The lab is also pioneering efforts in cloning a human heart. In the beginning of 2013, scientists at the institute began to look into replicating a heart in their revolutionary bioreactor, or bio-engineering chamber, which provides a space for the growth and maturity of cloned organs. They have been testing with rabbit hearts, and hope to scale up from there.

The process begins with removing all of the genetic material from the heart, leaving a shell of the muscle, commonly called a ghost heart because it has a white appearance after decellularization. The goal is to put pluripotent stem cells, or stem cells capable of separating into one of many cell types, into the ghost heart to generate a cloned heart from the patients own cells. Scientist are in the process of putting cells back into the heart, and Thurston says so far its working.

This gets rid of the need for donor hearts, said Thurston. Donor hearts have to be harvested within minutes to be viable for a transplant, he said, which is less time than it takes to harvest most other organs.

Thurston says the next step is for scientists to test pig hearts, which are identical to human hearts once all the genetic material is removed.

While the lab has made several scientific accomplishments including producing revolutionary drugs and treatments for cardiac arrhythmias, it boasts the discovery and naming of the M cell as its most significant breakthrough in heart research. Through the finding of the M cell, researchers were able to determine that the heart was a heterogeneous organ, meaning differences exist in the organs function and drug interaction. The cells were found to be the main reason for many types of arrhythmias, leading to the development of new strategies to fight the irregular heartbeats by targeting the M cells. Continued...

More here:
Media Lab to focus on heart research

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. It is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2 percent of cancer deaths in the United States, its incidence is expected to increase as the population ages.

AML has several subtypes, but treatment and prognosis are similar for all subtypes except M3 (acute promyelocytic leukemia), which is treated differently and has a much better prognosis. AML is treated initially with combination chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or hematopoietic stem cell transplant (HSCT). The latter can be either a bone marrow transplant (BMT) or transplant of blood stem cells isolated from peripheral blood (PBSC). In either case, it involves transplanting cells capable of restoring normal bone marrow function into a patient. Even though peripheral blood stem cells are used nowadays more often than bone marrow stem cells, all HSCT treatments are commonly referred to as bone marrow transplants and many academic institutions and associations still retain the term bone marrow transplant in their names.

An increasing number of patients in need of HSCT are over age 55, but many in this group are ruled ineligible. This is because the high-dose chemotherapy or chemotherapy combined with high doses of radiation used to prepare patients for HSCTstandard therapy for younger patientsare often deemed too harsh even for healthy looking older people. Indeed, in certain indications, more than one-third of patients over 50 treated with standard transplant regimens die as a direct consequence of treatment while almost half still have the leukemia recur.

Since more than half of AML patients are over 65 years old, new tactics are needed. For example, what if a patients existing bone marrow could be prepared prior to the transplant in the process called myeloconditioning in a way that eliminated the need for high-dose chemotherapy? This promising approach is being pursued by Actinium Pharmaceuticals, Inc., a New York City-based biotech company, under the guidance of its Chief Medical Officer, Dragan Cicic, M.D.

The companys approach to cancer treatment is based on combining the cancer-targeting precision of monoclonal antibodies (mAb) with the power of radioisotopes. To this end, it has developed two compounds currently in clinical trials, Iomab-B and Actimab-B.

Actiniums lead compound, Iomab-B, has been successfully harnessed as a myeloconditioning agent in Phase 1/2 trials involving more than 250 patients including cases of incurable blood cancers such as AML resistant to all available therapies. It has demonstrated the ability to prepare such patients for bone marrow transplants when no other treatment was indicated.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine 131 radioisotope. BC8 was developed at the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells but not on other tissues. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for HSCT in a number of blood cancer indications, including AML, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin disease, Non-Hodgkin lymphomas and multiple myeloma. When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

With any cancer treatment, success is usually increased when treatment initiates soon after diagnosis. This is especially true when projected survival is only a few months. Waiting for half that time to initiate a therapy can have a serious impact. Very significantly, treatment with Iomab-B prepares a patient for bone marrow transplant in only 10 days, compared to approximately six weeks required with traditional carea potentially vital difference in the face of a fast-evolving cancer.

Read the rest here:
Making Bone Marrow Transplants More Accessible for AML Patients with New Therapy

Recommendation and review posted by Bethany Smith

;

Dr. John Dick, a senior scientist at Princess Margaret Cancer Centre in Toronto, is shown in a handout photo.

TORONTO Canadian researchers have discovered a pre-leukemic stem cell that may be at the root of acute myeloid leukemia and also be the bad actor that evades chemotherapy and triggers a relapse in patients who have gone into remission.

Acute myeloid leukemia, or AML, is a rapidly progressing cancer of the blood and bone marrow that affects myeloid cells, which normally develop into mature red and white blood cells and platelets.

Leukemia develops when blood stem cells in the bone marrow make abnormal blood cells, which over time crowd out normal blood cells, affecting their ability to function as they should.

READ MORE:Could this new therapy kill cancer? Canadian doc thinks so

In a paper published online Wednesday in the journal Nature, researchers led by John Dick of Princess Margaret Cancer Centre in Toronto report on the discovery of a pre-leukemic stem cell the forerunner to leukemia stem cells that give rise to the disease.

A leukemia stem cell can lie dormant and theyre the ones that will sustain the growth of the leukemia, Dick said in an interview. The pre-leukemic guys are basically the ancestors that are on their way to becoming leukemia and becoming leukemic stem cells.

Dicks lab was the first to identify the existence of leukemia stem cells, in 1994, followed by the discovery of colon cancer stem cells in 2007.

Teasing out pre-leukemic stem cells from the blood of AML patients based on samples taken at diagnosis, after chemotherapy-induced remission, and then following recurrence advances the understanding of the genetic changes a normal cell has to go through before it turns into AML.

More here:
Scientists discover pre-leukemic stem cell at root of cancer

Recommendation and review posted by Bethany Smith

NBC says Tom Brokaw was diagnosed in August 2013 with multiple myeloma, a cancer affecting blood cells in the bone marrow. AP

Veteran newsmanTom Brokaws multiple myeloma diagnosis draws attention to an incurable cancer that researchers have made great strides in treating.

Before chemotherapy treatment for multiple myeloma was introduced in the 1950s, patients lived about one year after diagnosis, Dr. Frederic Reu, an associate staff physician at the Cleveland Clinic who specializes in blood cancers, explained to CBS News. Now, better treatments including stem cell transplants and non- chemotherapy medications that better target cancer cells can prolong life about seven to 10 years or longer after a diagnosis.

Brokaw, the 74-year-old former anchor of the NBC Nightly News, said in a statement that doctors are optimistic about his prognosis.

"With the exceptional support of my family, medical team and friends, I am very optimistic about the future and look forward to continuing my life, my work and adventures still to come," he said.

Play Video

In an interview in 2007 on The Early Show, Geraldine Ferraro discussed battling multiple myeloma, which she passed away from Saturday after a 12 ...

However, changes in DNA beyond our control might allow the cells to become cancerous myeloma cells, which then disrupt other areas throughout the body including the bones, kidneys, intestines and overall immune system.

Symptoms may include bone pain, fractures following minor trauma, anemia, weakness, fatigue, frequent infections, dehydration and frequent thirst, kidney failure and tumor growth.

These are the problems that indicate that the myeloma requires treatment, Reu explained.

The rest is here:
Tom Brokaw's multiple myeloma spotlights incurable cancer

Recommendation and review posted by Bethany Smith

1st TILS/Adoptive Cell Therapy Blog - Biopsy
The starting process of TILS or Adoptive Cell Therapy. 1st of many videos to come. Full written IV Melanoma blog at adriennes.blog.com.

By: Adrienne Lotton

View original post here:
1st TILS/Adoptive Cell Therapy Blog - Biopsy - Video

Recommendation and review posted by Bethany Smith

Advanced Stem Cell Therapy and PRP Treatment
Subscribe to Tv5 News Channel: http://goo.gl/NHJD9 Like us on Facebook: http://www.facebook.com/tv5newschannel Follow us on Twitter: https://twitter.co...

By: TV5 News

Read the rest here:
Advanced Stem Cell Therapy and PRP Treatment - Video

Recommendation and review posted by Bethany Smith

What is Stem Cell Therapy?
According to J. Peter Rubin, MD, Chair of the University of Pittsburgh #39;s Department of Plastic Surgery, stem cells are small cells that live within the tissu...

By: Smart Beauty Guide

Follow this link:
What is Stem Cell Therapy? - Video

Recommendation and review posted by Bethany Smith

Former Life Technologies executive Paul Grossman has joined Telegraph Hill Partners as a venture partner. Grossman previously was head of global strategy and corporate development at Life Tech, and he also held the same position at Invitrogen. Before he joined Invitrogen, Grossman held a variety of leadership roles at Applied Biosystems, including as a research scientist and patent attorney, VP of intellectual property, and VP of strategy and business development.

Becton Dickinson has appointed Amit Bhalla to be VP of global strategy and development. In the role, Bhalla will work with the senior management team to develop BD's overall strategy. Bhalla joins BD from Citi, where he has been director of equity research for life science tools and medical technology since 2006. Before joining Citi, he was VP of equity research for emerging medical technology at Morgan Stanley, and a technical operations R&D associate at Johnson and Johnson.

Ardy Arianpour has joined Pathway Genomics as chief strategy officer, the company said this week.

Arianpour most recently was senior VP of business development at Ambry Genetics, and during his 13-year career in the biotech sector he also has worked in senior sales and business development roles at Clinical Data, Cogenics, and Eurogentec North America. In his new post, Arianpour will lead the San Diego-based company's global strategy, strategic planning, and partnership activities.

Kevin Shianna has left the New York Genome Center, where he was most recently deputy scientific director of sequencing operations. His role has been taken over by Soren Germer and Dayna Oschwald, who both joined the NYGC in early 2012 as sequencing program managers.

Follow this link:
Gene by Gene's Clinical, Research Arrays Exempt from New Myriad BRCA Testing Agreement

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

13-Feb-2014

Contact: William Raillant-Clark w.raillant-clark@umontreal.ca 514-566-3813 University of Montreal

A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Universit de Montral discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression. That gene, known as Brg1 is a key regulator of leukemia stem cells that are the root cause of the disease, resistance to treatment and relapse.

Julie Lessard, principal investigator and her colleagues at IRIC have spent the past four years studying that gene in collaboration with another research group at Stanford University in California. The results of this study are reported this week in the prestigious scientific journal Blood.

"When we removed the Brg1 gene, the leukemia stem cells were unable to divide, survive and make new tumors. In other words, the cancer was permanently shut down", Lessard says.

One difficulty with targeting cancer stem cells is that many genes essential for their function are also essential for normal stem cells, and therapies targeting them can end up harming healthy stem cells as well. "Strikingly, we showed that the Brg1 gene is dispensable for the function of normal blood stem cells, making it a promising therapeutic target in leukemia treatment" explains Pierre Thibault, principal investigator at IRIC and co-author in this study.

The story showed striking results on laboratory animals and human leukemia cells but is still a long way from being transposed into the clinic. "The next step will be to develop a small-molecule inhibitor to successfully block Brg1 function in leukemia, thus demonstrating the clinical relevance of this discovery", states Guy Sauvageau, chief executive officer and principal investigator at IRIC as well as clinical hematologist at the Hpital Maisonneuve-Rosemont and co-author in this study.

The group is now performing experiments to identify such drugs that can disarm the Brg1 gene, thereby stopping leukemia stem cells from generating malignant cells.

Cancer stem cells appear to be more resistant to radiotherapy and chemotherapy than the 'bulk' of the tumor and therefore, are often responsible for cancer relapse. As such, inhibiting residual leukemia stem cells from dividing is the key to obtain irreversible impairment of tumor growth and long-term remission in patients. "Our recent studies identified the gene Brg1 as a regulator that governs the self-renewal, proliferative and survival capacity of leukemia stem cells. Therefore, targeting the Brg1 gene in leukemia stem cells may offer new therapeutic opportunities by preventing the disease from coming back", Lessard concludes.

Original post:
A promising new approach for treating leukemia discovered

Recommendation and review posted by Bethany Smith

Precise and easy ways to rewrite human genes could finally provide the tools that researchers need to understand and cure some of our most deadly genetic diseases.

Over the last decade, as DNA-sequencing technology has grown ever faster and cheaper, our understanding of the human genome has increased accordingly. Yet scientists have until recently remained largely ham-fisted when theyve tried to directly modify genes in a living cell. Take sickle-cell anemia, for example. A debilitating and often deadly disease, it is caused by a mutation in just one of a patients three billion DNA base pairs. Even though this genetic error is simple and well studied, researchers are helpless to correct it and halt its devastating effects.

Now there is hope in the form of new genome-engineering tools, particularly one called CRISPR. This technology could allow researchers to perform microsurgery on genes, precisely and easily changing a DNA sequence at exact locations on a chromosome. Along with a technique called TALENs, invented several years ago, and a slightly older predecessor based on molecules called zinc finger nucleases, CRISPR could make gene therapies more broadly applicable, providing remedies for simple genetic disorders like sickle-cell anemia and eventually even leading to cures for more complex diseases involving multiple genes. Most conventional gene therapies crudely place new genetic material at a random location in the cell and can only add a gene. In contrast, CRISPR and the other new tools also give scientists a precise way to delete and edit specific bits of DNAeven by changing a single base pair. This means they can rewrite the human genome at will.

It is likely to be at least several years before such efforts can be developed into human therapeutics, but a growing number of academic researchers have seen some preliminary success with experiments involving sickle-cell anemia, HIV, and cystic fibrosis (see table below). One is Gang Bao, a bioengineering researcher at the Georgia Institute of Technology, who has already used CRISPR to correct the sickle-cell mutation in human cells grown in a dish. Bao and his team started the work in 2008 using zinc finger nucleases. When TALENs came out, his group switched quickly, says Bao, and then it began using CRISPR when that tool became available. While he has ambitions to eventually work on a variety of diseases, Bao says it makes sense to start with sickle-cell anemia. If we pick a disease to treat using genome editing, we should start with something relatively simple, he says. A disease caused by a single mutation, in a single gene, that involves only a single cell type.

In little more than a year, CRISPR has begun reinventing genetic research.

Bao has an idea of how such a treatment would work. Currently, physicians are able to cure a small percentage of sickle-cell patients by finding a human donor whose bone marrow is an immunological match; surgeons can then replace some of the patients bone marrow stem cells with donated ones. But such donors must be precisely matched with the patient, and even then, immune rejectiona potentially deadly problemis a serious risk. Baos cure would avoid all this. After harvesting blood cell precursors called hematopoietic stem cells from the bone marrow of a sickle-cell patient, scientists would use CRISPR to correct the defective gene. Then the gene-corrected stem cells would be returned to the patient, producing healthy red blood cells to replace the sickle cells. Even if we can replace 50 percent, a patient will feel much better, says Bao. If we replace 70 percent, the patient will be cured.

Though genome editing with CRISPR is just a little over a year old, it is already reinventing genetic research. In particular, it gives scientists the ability to quickly and simultaneously make multiple genetic changes to a cell. Many human illnesses, including heart disease, diabetes, and assorted neurological conditions, are affected by numerous variants in both disease genes and normal genes. Teasing out this complexity with animal models has been a slow and tedious process. For many questions in biology, we want to know how different genes interact, and for this we need to introduce mutations into multiple genes, says Rudolf Jaenisch, a biologist at the Whitehead Institute in Cambridge Massachusetts. But, says Jaenisch, using conventional tools to create a mouse with a single mutation can take up to a year. If a scientist wants an animal with multiple mutations, the genetic changes must be made sequentially, and the timeline for one experiment can extend into years. In contrast, Jaenisch and his colleagues, including MIT researcher Feng Zhang (a 2013 member of our list of 35 innovators under 35), reported last spring that CRISPR had allowed them to create a strain of mice with multiple mutations in three weeks.

Genome GPS

Original post:
CRISPR is the technology that could allow researchers to perform microsurgery on genes

Recommendation and review posted by Bethany Smith

How Alternative Medicine Has Infiltrated U.S. Medical Schools - Steve Salzberg
Presented by the National Capital Area Skeptics - http://www.ncas.org. Alternative medicine has become very popular over the past two decades, thanks to relentless ...

By: NCASVideo

Read more here:
How Alternative Medicine Has Infiltrated U.S. Medical Schools - Steve Salzberg - Video

Recommendation and review posted by Bethany Smith

Swathi Rao PA-C, an Indianapolis Clinician, Graduates to Become a Part of the Elite Group of Certified Practitioners by the Institute for Functional Medicine

Swathi has chosen to focus her expertise in Functional medicine for many timely reasons. According to Federal Way, WA; February 10, 2014: "Of total healthcare costs in the United States, more than 75% is due to chronic conditions." Functional medicine incorporates the latest in genetic science and systems biology, and also enables health care practitioners to practice proactive, predictive, and personalized medicine while empowering patients to take an active role in their own health.

As a graduate of The Institute for Functional Medicines Certification Program (IFMCP), Swathi Rao is uniquely trained in the functional medicine model to identify and treat the root causes of chronic disease. In order to achieve the designation of IFM Certified Practitioner, Swathi has completed 7 onsite training seminars and passed stringent written and case study evaluations.

Swathi joins an elite group of 124 practitioners who are among the first graduates of IFMs Certification Program.

About Swathi Rao PA-C Swathi is a Physician Assistant who works at Excell for Life Family Care & Pediatrics. She obtained her Physician Assistant Degree at Buter University and her Bachelors at Indiana University. To arrange an interview with Swathi please contact: Samantha Crispin, 317-660-0888 ext. 205, scrispin@excellforlife.com

About The Institute for Functional Medicine The Institute for Functional Medicine believes that good health and vitality are essential to the human spirit. The mission of IFM is to serve the highest expression of individual health through widespread adoption of functional medicine as the standard of care.

Functional medicine is a personalized, systems-oriented model that empowers patients and practitioners to achieve the highest expression of health by working in collaboration to address the underlying causes of disease. The primary drivers of the chronic disease epidemic are the complex daily interactions among an individuals genetics, environment, and lifestyle choices. Functional medicine addresses these underlying causes of disease and equips healthcare practitioners to help their patients manage this complex, interconnected web. For more information, please visit: http://functionalmedicine.org/.

About Functional Medicine The rising rates of chronic disease are creating a huge burden on the economy and the current health care system is not adequately addressing the problem. Conventional health care is rooted in an acute-care model focused on rapid diagnosis and long-term pharmaceutical interventions. Functional medicine is a model for 21st century health care that focuses on identifying and addressing the underlying causes of chronic disease by recognizing that each patient is biochemically unique, a product of the continuous interaction between their genes, their environment, and their lifestyle choices. Only by finding the specific causes of each patients disease and providing treatment that is individualized to that patient will we be able to reverse the epidemic of chronic disease.

See original here:
Swathi Rao PA-C, an Indianapolis Clinician, Graduates to Become a Part of the Elite Group of Certified Practitioners ...

Recommendation and review posted by Bethany Smith

Minecraft-MOD Advanced Genetics(Genetica avanzada)
Hola amigos de youtube espero que esten muy bien! 😀 Y pues bueno esta ves les traigo un nuevo mod Genetica avanzada (en espaol) Aqui el link de descarga de...

By: Sebpper Torres

Link:
Minecraft-MOD Advanced Genetics(Genetica avanzada) - Video

Recommendation and review posted by Bethany Smith

Genetics Inheritance
Stop-motion animation demonstrating the genetics of meiosis and inheritance, made by group B4 from bridging course class of 2014.

By: FYB Sydney

Read the original here:
Genetics & Inheritance - Video

Recommendation and review posted by Bethany Smith

The Angus Report, Feb. 10, 2014: Building Better Genetics
Cattlemen like Texas Angus breeder Jimmy Goode rely on DNA information from the Zoetis HD 50K test and genomic-enhanced EPDs to make the best possible select...

By: Angus TV

Read this article:
The Angus Report, Feb. 10, 2014: Building Better Genetics - Video

Recommendation and review posted by Bethany Smith

Talent vs Training
Which is more important - genetics or hard work? DAILY EPISODES, answering your burning questions. Watch 5 episodes before anybody else: http://bit.ly/1n5llR...

By: AsapSCIENCE

See the article here:
Talent vs Training - Video

Recommendation and review posted by Bethany Smith

Attack Of The B-Team - Episode 12 - Advanced Genetics
A brand new Mod pack from the Fantastic team over at Technic! Attack Of The B-Team This new pack is a large modpack with big ores, and a mad science theme! N...

By: Gaming On Caffeine

See the original post:
Attack Of The B-Team - Episode 12 - Advanced Genetics - Video

Recommendation and review posted by Bethany Smith

Are Genetics Important For Bodybuilding?
Get Instant Access To My Complete, No B.S, Step-By-Step Muscle Building Fat Loss Programs: http://www.BodyTransformationTruth.com ** Connect With Me ...

By: Sean Nalewanyj

Originally posted here:
Are Genetics Important For Bodybuilding? - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics 1.4/ MC1.6.4 - Gene Removal
Minecraft 1.6.4 Part 3 of Advanced Genetics tutorial in which i show you how to remove an unwanted gene from your own DNA. Please leave a like if these video...

By: Corerupt83

Read more:
Advanced Genetics 1.4/ MC1.6.4 - Gene Removal - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics 1.4/ MC1.6.4 - DNA Cloning and Sampling Mobs
Minecraft 1.6.4 Part 4 of Advanced Genetics tutorial where i show you how to clone your DNA and imprint it onto other mobs which you can then spawn in the wo...

By: Corerupt83

Visit link:
Advanced Genetics 1.4/ MC1.6.4 - DNA Cloning and Sampling Mobs - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics 1.4/ MC1.6.4 - DNA Combining and Analyzing
Minecraft 1.6.4 Part 2 of Advanced Genetics tutorial explaining how to process your ability gene and apply it to your own DNA. Please leave a like if these v...

By: Corerupt83

See the original post:
Advanced Genetics 1.4/ MC1.6.4 - DNA Combining and Analyzing - Video

Recommendation and review posted by Bethany Smith

Advanced Genetics 1.4/ MC1.6.4 - Power Supply and Gene Creation Basics
Minecraft 1.6.4 Part 1 of Advanced Genetics tutorial explaining what power you can use and the first steps you need to take when using this mod. Please leave...

By: Corerupt83

Read the original here:
Advanced Genetics 1.4/ MC1.6.4 - Power Supply and Gene Creation Basics - Video

Recommendation and review posted by Bethany Smith

Reveal Workshop - Character Genetics
The Reveal Workshop is an interactive, engaging, transformative executive group coaching experience that #39;s jam-packed full of strategies and tools that the h...

By: Spirit of Life Church

Continued here:
Reveal Workshop - Character Genetics - Video

Recommendation and review posted by Bethany Smith

Justin Clark #39;s Speech at the Hannah #39;s Hope Ball
The mission of Hannah #39;s Hope Fund (HHF) is to raise funds for a treatment and cure of GAN. Lori and Matt Sames co-founded HHF following the diagnosis of thei...

By: hannahshopefund

Read the original:
Justin Clark's Speech at the Hannah's Hope Ball - Video

Recommendation and review posted by Bethany Smith

Milwaukee, WI (PRWEB) February 13, 2014

The American Society of Gene & Cell Therapy (ASGCT) has announced its 2014 Award Series as part of its 17th Annual Meeting held May 21-24, 2014 at the Marriott Wardman Park in Washington, DC.

ASGCT is honored to recognize Dr. Luigi Naldini from the University Vita-Salute San Raffaele as the recipient of the 2014 Outstanding Achievement Award (OAA). The OAA recognizes an ASGCT Active Member who has achieved a pioneering research success, a specific high impact accomplishment, or a lifetime of significant scientific contributions to the fields of gene and/or cell therapy. Dr. Naldini will present a plenary lecture at the ASGCT 17th Annual Meeting on May 22nd.

Barbara Netter and Edward Netter (deceased) are the recipients of this years Distinguished Service Award. Both will be acknowledged on May 22nd during the ASGCT 17th Annual Meeting for their creation of the Alliance for Cancer Gene Therapy (ACGT). Since its inception in 2001, the foundation has provided $25 million in funding to sponsor medical institutions and researchers dedicated to focusing genetic therapeutics for the treatment of Cancer.

The Outstanding New Investigator Awards are given in recognition of scientists conducting original research in basic science, technology development or clinical translation. Each of the following recipients will present a retrospective of his work on May 23rd during the ASGCT Annual Meeting:

o Brian Brown, PhD - Mt. Sinai School of Medicine o Charles Gersbach, PhD Duke University o Scott Harper, PhD - Ohio State University & Nationwide Children's Hospital o Daniel Powell, PhD - University of Pennsylvania

ASGCT congratulates each of its award winners and is appreciative for their continued contributions to the field of gene and cell therapy.

The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.

###

More:
ASGCT Announces 2014 Award Series for Contributions to the Field of Genetic and Cellular Therapy

Recommendation and review posted by Bethany Smith